Six Companies Persist in Cell Therapy Development Amid Exits by Takeda and Novo Nordisk

Several companies remain active in the cell therapy sector despite notable exits by major pharmaceutical firms and closures among smaller biotech organizations. Industry giants such as Takeda and Novo Nordisk have recently withdrawn from the field, while some smaller players have ceased operations altogether. However, six companies continue to pursue advancements in cell therapy, aiming to explore its potential further.

The persistence of these six entities comes at a time when challenges in the cell therapy space have led others to scale back or exit entirely. The departure of Takeda and Novo Nordisk highlights shifting priorities within larger pharmaceutical firms, while financial constraints and operational hurdles have forced smaller biotechs to shut down. Despite these setbacks across the industry, these remaining companies are maintaining their focus on developing innovative treatments through cell-based modalities. Their continued presence underscores ongoing efforts to address scientific, regulatory, and commercial obstacles associated with this therapeutic approach.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

Related posts:

DrugPatentWatch Advocates for Raw Data Access in Biopharma, Citing Weeks-Long Delays in Traditional Analyst Reports Study Finds One-Size-Fits-All Sensory Rooms Ineffective for Autistic Adults Study Identifies GhMYB5 as Key Regulator of Brown Cotton Pigmentation Through CHS Activity Deep Learning Models Achieve Near-Perfect Accuracy in Melanoma Detection by Integrating Patient Data

Author

GOAI